Two things before anyone answers the substance.
First, the context in the first post is clear and specific. Second, the question is framed so that an answer can actually address it. Both are the norm here and both matter more than they sound.
Two things before anyone answers the substance.
First, the context in the first post is clear and specific. Second, the question is framed so that an answer can actually address it. Both are the norm here and both matter more than they sound.
Type 2 diabetes: the population with the largest evidence base for these compounds. The SURPASS and SUSTAIN programmes established glycaemic benefit. The renal and cardiovascular benefit evidence is separate from the glycaemic benefit evidence.
post #18 answers the question as asked. The question underneath it is different.
For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.
Read the full topic (23 posts)
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Hypertension improvement and when medication needs revisiting — a second dataset
Posting this under the heading it deserves: Hypertension improvement and when medication needs revisiting — a second dataset Everything below is what sits behind that. General question, not a request for…
|
+126 | 133 | 22k | 21mo |
|
Obstructive sleep apnoea and a hard endpoint in this class
On the subject in the title: Obstructive sleep apnoea and a hard endpoint in this class Working notes rather than a conclusion. Asking about a population rather than about a person. The published trials in…
|
+120 | 129 | 1.8k | 13mo |
|
Revisiting: Heart failure with preserved ejection fraction: symptom endpoints
On the subject in the title: Revisiting: Heart failure with preserved ejection fraction: symptom endpoints Working notes rather than a conclusion. General question, not a request for advice about my own care…
|
+4 | 8 | 43k | 17mo |
|
Cardiovascular risk: reading the outcome trials as a set
Cardiovascular risk: reading the outcome trials as a set Writing it up because I had to work it out twice and would rather nobody else did. Asking about a population rather than about a person. The published…
|
4 | 12k | 5mo | |
|
[2026 update] Gastro-oesophageal reflux: improving or worsening?
Asking directly, because I could not find a straight answer: Gastro-oesophageal reflux: improving or worsening? General question, not a request for advice about my own care — I know the difference and I would…
|
3 | 782 | 13mo |
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Asking about a compound your prescriber has not heard of — one year on
On the subject in the title: Asking about a compound your prescriber has not heard of — one year on Working notes rather than a conclusion. General question, not a request for advice about my own care — I…
|
+11 | 15 | 3.7k | 19mo |
|
What a good consultation looks like from the other side
What a good consultation looks like from the other side — that is the question, and I have not found it answered plainly anywhere I have looked. Asking about a population rather than about a person. The…
|
+57 | 62 | 4.9k | 22h |
|
Adolescents: a distinct evidence base — one year on
Posting this under the heading it deserves: Adolescents: a distinct evidence base — one year on Everything below is what sits behind that. General question, not a request for advice about my own care — I know…
|
+78 | 88 | 9.3k | 3mo |
|
Heart failure with preserved ejection fraction: symptom endpoints
Heart failure with preserved ejection fraction: symptom endpoints — setting out what I have, and where I think it stops being reliable. Asking about a population rather than about a person. The published…
|
+19 | 23 | 311 | 12d |
|
What to bring: records that a clinician can actually use
Asking directly, because I could not find a straight answer: What to bring: records that a clinician can actually use Asking about a population rather than about a person. The published trials in this class…
|
+15 | 19 | 6.4k | 1d |